HomeCompareGRTS vs MRK

GRTS vs MRK: Dividend Comparison 2026

GRTS yields 6211.18% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GRTS wins by $514736922231177.88M in total portfolio value
10 years
GRTS
GRTS
● Live price
6211.18%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$514736922231177.94M
Annual income
$498,935,081,000,370,800,000.00
Full GRTS calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — GRTS vs MRK

📍 GRTS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRTSMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRTS + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GRTS pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRTS
Annual income on $10K today (after 15% tax)
$527,950.31/yr
After 10yr DRIP, annual income (after tax)
$424,094,818,850,315,200,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, GRTS beats the other by $424,094,818,850,315,200,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRTS + MRK for your $10,000?

GRTS: 50%MRK: 50%
100% MRK50/50100% GRTS
Portfolio after 10yr
$257368461115589.00M
Annual income
$249,467,540,500,185,400,000.00/yr
Blended yield
96.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

GRTS
Analyst Ratings
7
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$4.67
+14403.1% upside vs current
Range: $3.00 — $6.00
Altman Z
-9.7
Piotroski
1/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRTS buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRTSMRK
Forward yield6211.18%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$514736922231177.94M$57.7K
Annual income after 10y$498,935,081,000,370,800,000.00$10,113.78
Total dividends collected$513674666624982.00M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$4.67$128.54

Year-by-year: GRTS vs MRK ($10,000, DRIP)

YearGRTS PortfolioGRTS Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$631,818$621,118.01$11,213$373.04+$620.6KGRTS
2$37,352,078$36,676,032.53$12,667$512.06+$37.34MGRTS
3$2,066,348,794$2,026,382,070.58$14,439$708.14+$2066.33MGRTS
4$106,978,454,906$104,767,461,696.78$16,640$988.16+$106978.44MGRTS
5$5,183,619,185,269$5,069,152,238,519.27$19,432$1,394.07+$5183619.17MGRTS
6$235,102,301,025,325$229,555,828,497,087.03$23,057$1,992.90+$235102301.00MGRTS
7$9,981,906,672,630,884$9,730,347,210,533,788.00$27,889$2,894.79+$9981906672.60MGRTS
8$396,781,870,195,426,800$386,101,230,055,711,700.00$34,518$4,286.29+$396781870195.39MGRTS
9$14,768,075,916,642,124,000$14,343,519,315,533,017,000.00$43,912$6,494.35+$14768075916642.08MGRTS
10$514,736,922,231,177,940,000$498,935,081,000,370,800,000.00$57,714$10,113.78+$514736922231177.88MGRTS

GRTS vs MRK: Complete Analysis 2026

GRTSStock

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Full GRTS Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this GRTS vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRTS vs SCHDGRTS vs JEPIGRTS vs OGRTS vs KOGRTS vs MAINGRTS vs JNJGRTS vs ABBVGRTS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.